Celcuity Inc. (CELC) is rising to prominence within oncology with bold ambitions and a science-driven edge. At the heart of its progress is Gedatolisib, a next-generation therapy designed to shut down the PI3K/AKT/mTOR pathway more completely than single-target drugs ever could. This multi-target approach is a potential game-changer for treating solid tumors.
Energy around the pipeline is surging. With late-stage clinical trials advancing, an NDA now submitted to the FDA under its Real-Time Oncologyiplet Review program, and a cash position strong enough to fuel operations for years, Celcuity stands at a defining crossroads. The company is not just moving forward; it's accelerating toward a moment that could reshape treatment options in advanced breast cancer and beyond.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.